Inbal Goldshtein1,2, David M Steinberg3, Jacob Kuint1,4, Gabriel Chodick1,2, Yaakov Segal5, Shirley Shapiro Ben David5, Amir Ben-Tov1,4. 1. Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel. 2. Department of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel. 3. Department of Statistics and Operations Research, Tel Aviv University, Tel-Aviv, Israel. 4. Department of Pediatrics, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel. 5. Health Division, Maccabi Healthcare Services, Tel-Aviv, Israel.
Abstract
Importance: Pregnant women were excluded from the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) preauthorization trial. Therefore, observational data on vaccine safety for prenatally exposed newborns are critical to inform recommendations on maternal immunization. Objective: To examine whether BNT162b2 mRNA vaccination during pregnancy is associated with adverse neonatal and early infant outcomes among the newborns. Design, Setting, and Participants: Population-based cohort study comprising all singleton live births in March through September 2021, within a large state-mandated health care organization in Israel, followed up until October 31, 2021. Exposure: Maternal BNT162b2 mRNA vaccination during pregnancy. Main Outcomes and Measures: Risk ratios (RR) of preterm birth, small birth weight for gestational age (SGA), congenital malformations, all-cause hospitalizations, and infant death. Stabilized inverse probability weighting was used to adjust for maternal age, timing of conception, parity, socioeconomic status, population subgroup, and maternal influenza immunization status. Results: The cohort included 24 288 eligible newborns (49% female, 96% born at ≥37 weeks' gestation), of whom 16 697 were exposed (n = 2134 and n = 9364 in the first and second trimesters, respectively) to maternal vaccination in utero. Median (IQR) follow-up after birth was 126 days (76-179) among exposed and 152 days (88-209) among unexposed newborns. No substantial differences were observed in preterm birth rates between exposed and unexposed newborns (RR = 0.95; 95% CI, 0.83-1.10) or SGA (RR = 0.97; 95% CI, 0.87-1.08). No significant differences were observed in the incidence of all-cause neonatal hospitalizations (RR = 0.99; 95% CI, 0.88-1.12), postneonatal hospitalizations after birth (RR = 0.95; 95% CI, 0.84-1.07), congenital anomalies (RR = 0.69; 95% CI, 0.44-1.04), or infant mortality over the study period (RR = 0.84; 95% CI, 0.43-1.72). Conclusions and Relevance: This large population-based study found no evident differences between newborns of women who received BNT162b2 mRNA vaccination during pregnancy, vs those of women who were not vaccinated, and contributes to current evidence in establishing the safety of prenatal vaccine exposure to the newborns. Interpretation of study findings is limited by the observational design.
Importance: Pregnant women were excluded from the BNT162b2 messenger RNA (mRNA) COVID-19 vaccine (Pfizer-BioNTech) preauthorization trial. Therefore, observational data on vaccine safety for prenatally exposed newborns are critical to inform recommendations on maternal immunization. Objective: To examine whether BNT162b2 mRNA vaccination during pregnancy is associated with adverse neonatal and early infant outcomes among the newborns. Design, Setting, and Participants: Population-based cohort study comprising all singleton live births in March through September 2021, within a large state-mandated health care organization in Israel, followed up until October 31, 2021. Exposure: Maternal BNT162b2 mRNA vaccination during pregnancy. Main Outcomes and Measures: Risk ratios (RR) of preterm birth, small birth weight for gestational age (SGA), congenital malformations, all-cause hospitalizations, and infant death. Stabilized inverse probability weighting was used to adjust for maternal age, timing of conception, parity, socioeconomic status, population subgroup, and maternal influenza immunization status. Results: The cohort included 24 288 eligible newborns (49% female, 96% born at ≥37 weeks' gestation), of whom 16 697 were exposed (n = 2134 and n = 9364 in the first and second trimesters, respectively) to maternal vaccination in utero. Median (IQR) follow-up after birth was 126 days (76-179) among exposed and 152 days (88-209) among unexposed newborns. No substantial differences were observed in preterm birth rates between exposed and unexposed newborns (RR = 0.95; 95% CI, 0.83-1.10) or SGA (RR = 0.97; 95% CI, 0.87-1.08). No significant differences were observed in the incidence of all-cause neonatal hospitalizations (RR = 0.99; 95% CI, 0.88-1.12), postneonatal hospitalizations after birth (RR = 0.95; 95% CI, 0.84-1.07), congenital anomalies (RR = 0.69; 95% CI, 0.44-1.04), or infant mortality over the study period (RR = 0.84; 95% CI, 0.43-1.72). Conclusions and Relevance: This large population-based study found no evident differences between newborns of women who received BNT162b2 mRNA vaccination during pregnancy, vs those of women who were not vaccinated, and contributes to current evidence in establishing the safety of prenatal vaccine exposure to the newborns. Interpretation of study findings is limited by the observational design.
Authors: Azar Mehrabadi; Linda Dodds; Noni E MacDonald; Karina A Top; Eric I Benchimol; Jeffrey C Kwong; Justin R Ortiz; Ann E Sprague; Laura K Walsh; Kumanan Wilson; Deshayne B Fell Journal: JAMA Date: 2021-06-08 Impact factor: 56.272
Authors: Malini DeSilva; Flor M Munoz; Mark Mcmillan; Alison Tse Kawai; Helen Marshall; Kristine K Macartney; Jyoti Joshi; Martina Oneko; Annette Elliott Rose; Helen Dolk; Francesco Trotta; Hans Spiegel; Sylvie Tomczyk; Anju Shrestha; Sonali Kochhar; Elyse O Kharbanda Journal: Vaccine Date: 2016-07-18 Impact factor: 3.641
Authors: Kathryn J Gray; Evan A Bordt; Caroline Atyeo; Elizabeth Deriso; Babatunde Akinwunmi; Nicola Young; Aranxta Medina Baez; Lydia L Shook; Dana Cvrk; Kaitlyn James; Rose De Guzman; Sara Brigida; Khady Diouf; Ilona Goldfarb; Lisa M Bebell; Lael M Yonker; Alessio Fasano; S Alireza Rabi; Michal A Elovitz; Galit Alter; Andrea G Edlow Journal: Am J Obstet Gynecol Date: 2021-03-26 Impact factor: 8.661
Authors: Tom T Shimabukuro; Shin Y Kim; Tanya R Myers; Pedro L Moro; Titilope Oduyebo; Lakshmi Panagiotakopoulos; Paige L Marquez; Christine K Olson; Ruiling Liu; Karen T Chang; Sascha R Ellington; Veronica K Burkel; Ashley N Smoots; Caitlin J Green; Charles Licata; Bicheng C Zhang; Meghna Alimchandani; Adamma Mba-Jonas; Stacey W Martin; Julianne M Gee; Dana M Meaney-Delman Journal: N Engl J Med Date: 2021-04-21 Impact factor: 91.245
Authors: S Bookstein Peretz; N Regev; L Novick; M Nachshol; E Goffer; A Ben-David; K Asraf; R Doolman; E Sapir; G Regev Yochay; Y Yinon Journal: Ultrasound Obstet Gynecol Date: 2021-07-01 Impact factor: 7.299
Authors: Paola Ayala-Ramírez; Marcelo González; Carlos Escudero; Laura Quintero-Arciniegas; Fernanda R Giachini; Raiany Alves de Freitas; Alicia E Damiano; Reggie García-Robles Journal: Front Physiol Date: 2022-03-30 Impact factor: 4.566
Authors: Edwige Péju; Félicie Belicard; Stein Silva; Sami Hraiech; Benoît Painvin; Toufik Kamel; Arnaud W Thille; Antoine Goury; David Grimaldi; Boris Jung; Michael Piagnerelli; Hadrien Winiszewski; Merce Jourdain; Mathieu Jozwiak Journal: Intensive Care Med Date: 2022-08-17 Impact factor: 41.787
Authors: Sigal Klipstein; Jodie A Dionne; Eve C Feinberg; Jennifer F Kawwass; Samantha M Pfeifer; Peter N Schlegel; Catherine Racowsky Journal: Fertil Steril Date: 2022-06-29 Impact factor: 7.490
Authors: Deshayne B Fell; Sheryll Dimanlig-Cruz; Annette K Regan; Siri E Håberg; Christopher A Gravel; Laura Oakley; Gillian D Alton; Eszter Török; Tavleen Dhinsa; Prakesh S Shah; Kumanan Wilson; Ann E Sprague; Darine El-Chaâr; Mark C Walker; Jon Barrett; Nannette Okun; Sarah A Buchan; Jeffrey C Kwong; Sarah E Wilson; Sandra I Dunn; Shannon E MacDonald; Shelley D Dougan Journal: BMJ Date: 2022-08-17